InnoTherapy
Financials
Estimates*
KRW | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 203m | 512m | 693m | 596m | 507m | 370m | 1.3b |
% growth | - | 152 % | 35 % | (14 %) | (15 %) | (27 %) | 257 % |
EBITDA | (2.2b) | (2.3b) | (3.5b) | (3.2b) | (3.9b) | (3.8b) | (3.2b) |
% EBITDA margin | (1082 %) | (443 %) | (502 %) | (529 %) | (762 %) | (1040 %) | (243 %) |
Profit | (3.0b) | (2.6b) | (4.0b) | (3.0b) | (5.0b) | (6.0b) | (5.0b) |
% profit margin | (1484 %) | (503 %) | (576 %) | (511 %) | (992 %) | (1614 %) | (380 %) |
EV / revenue | - | - | 86.3x | 137.4x | 134.4x | 149.6x | 47.8x |
EV / EBITDA | - | - | -17.2x | -25.9x | -17.6x | -14.4x | -19.6x |
R&D budget | - | - | - | 1.2b | 1.4b | 1.3b | 1.2b |
R&D % of revenue | - | - | - | 208 % | 281 % | 362 % | 93 % |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | - | |
N/A | N/A | IPO | |
Total Funding | - |
Recent News about InnoTherapy
EditInnoTherapy specializes in developing innovative blood technology solutions, particularly in the area of hemostasis, which is the process of stopping bleeding. The company leverages protein-based advancements to create cutting-edge medical products. InnoTherapy serves healthcare providers and medical institutions, primarily operating in the Asian market. The business model includes research and development collaborations, licensing agreements, and strategic partnerships. Revenue is generated through product sales, licensing fees, and collaborative research funding. The company is committed to global marketing and overseas clinical study approvals to expand its market reach.
Keywords: hemostasis, blood technology, protein advancements, healthcare innovation, medical products, R&D collaborations, licensing, strategic partnerships, global marketing, clinical studies.